CCM
CINC

CAAS Capital Management’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

CAAS Capital Management’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75,000
Closed -$1.32M – 1056
2022
Q1 		$1.32M Buy
+75,000
New +$1.54M 0.05% 268

Other funds holding CINC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

CAAS Capital Management's CINC Position: Q2 2022 in Review

CAAS Capital Management sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q2 2022, closing a stake of 75,000 shares — an estimated $1.32M sold.

CAAS Capital Management first reported a position in CINC in Q1 2022 and held it in 1 quarter. The position peaked at $1.32M in Q1 2022. 57 funds tracked by Wall St. Rank hold CINC as of Q2 2022.

  • CAAS Capital Management reported no remaining CinCor Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • CAAS Capital Management sold 75,000 CinCor Pharma, Inc. Common Stock shares in Q2 2022, an estimated $1.32M.
  • CAAS Capital Management first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • CAAS Capital Management's CinCor Pharma, Inc. Common Stock position peaked at $1.32M in Q1 2022.
  • 57 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q2 2022.

Based on CAAS Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.